疟原虫延伸因子1α疫苗在完全弗氏佐剂中的免疫应答
研究以恶性疟原虫延伸因子1α(PfEF-1α)为保守胞内抗原候选,在啮齿模型中用完全弗氏佐剂(CFA)乳化免疫,评估存活率、抗体产生和T细胞细胞因子应答。结果显示免疫组存活率提高50%,存活小鼠中一半无虫血症,抗原特异性IgG终点滴度较对照高16倍,并鉴定出可诱导IFN-γ的表位410-FAIRDMRQTI-419。
要点
- rPfEF-1α加CFA免疫使小鼠存活率提高50%,存活者中一半无虫血症。
- 免疫组抗原特异性IgG终点滴度较BSA加CFA组高16倍,IgG1和IgG2c显著升高。
- 体外T细胞应答以CD4+IFN-γ+为主,表位410-FAIRDMRQTI-419可诱导IFN-γ。
核心结论
- PfEF-1α加CFA可驱动保护性T细胞应答和抗体产生,提示胞内抗原可用于疟疾疫苗靶点开发。
研究设计与样本
- 在啮齿模型中分析CFA乳化PfEF-1α的体内疫苗效力、抗体产生和体外T细胞细胞因子试验。
- 采用免疫信息学预测表位,并通过体外T细胞研究验证新肽候选。
主要发现
- rPfEF-1α加CFA免疫组存活率提高50%,存活小鼠中一半完全无虫血症,而BSA加CFA组全部出现虫血症。
- T细胞与树突状细胞共培养后,PfEF-1α特异性体外T细胞试验显示CD4+IFN-γ+分泌为主导应答,其次为CD8+IFN-γ+和CD4+IL-4+亚群。
- rPfEF-1α加CFA诱导强体液免疫,抗原特异性IgG终点滴度较BSA加CFA组高16倍,IgG1和IgG2c滴度显著升高。
- 经计算机预测并验证的PfEF-1α表位410-FAIRDMRQTI-419在体外C57BL/6 T细胞研究中诱导IFN-γ分泌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most studies of malarial vaccines focused on increasing immunity against target molecules on the surface of Plasmodium spp. parasites. While the surface antigens are variable among all Plasmodium spp., intracellular antigens are highly conserved, and thus, intracellular targets must be studied as vaccine candidates. However, there is a scarcity of intracellular vaccine candidates in Plasmodium parasites. In this study, immune responses induced by complete Freund's Adjuvant (CFA) emulsified with an elongation factor-1 alpha of P. falciparum (PfEF-1α) was analyzed as a Plasmodium spp. conserved vaccine candidate. In vivo vaccine efficacy, antibody production, and ex vivo T-cell cytokine assays were analyzed to validate the potential of PfEF-1α at CFA-based formulation in a rodent model. Immunoinformatics was employed to predict potential vaccine epitope candidates, and a novel peptide candidate was validated by ex vivo T-cell study. The survival rate of the rPfEF-1α plus CFA-immunized group was increased by 50% and among the survived mice, half proportion of mice was not patent at all while all BSA plus CFA showed the patency. Upon co-culturing of T cells with dendritic cells, PfEF-1α-specific ex vivo T-cell assay revealed CD4+IFN-γ+ secretion as the dominant immune response, followed by CD8+IFN-γ+ and CD4+IL-4+ subsets. Immunization with rPfEF-1-α plus CFA elicited robust humoral immunity, demonstrating a 16-fold higher antigen-specific IgG endpoint titer compared to the BSA plus CFA-immunized group. IgG1 and IgG2c titers in rPfEF-1α plus CFA-immunized mice were highly elevated over BSA plus CFA-immunized group. Furthermore, the PfEF-1α epitope (410-FAIRDMRQTI-419), identified through in silico prediction and validated, induced IFN-γ secretion in ex vivo C57BL/6 T-cell study. These results demonstrate PfEF-1α's capacity to drive protective T-cell responses and antibody production with CFA adjuvant. Our findings suggest the use of intracellular antigen for development of malaria vaccine targets.
引用
- Hong H, Eom TH, Lee E, et al. Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant. Vaccine. 2026. PMID: 41616650. doi:10.1016/j.vaccine.2026.128279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。